Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...